---
title: "Hunan Warrant Pharmaceutical Co.,Ltd. (688799.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688799.SH.md"
symbol: "688799.SH"
name: "Hunan Warrant Pharmaceutical Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T09:39:04.487Z"
locales:
  - [en](https://longbridge.com/en/quote/688799.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688799.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688799.SH.md)
---

# Hunan Warrant Pharmaceutical Co.,Ltd. (688799.SH)

## Company Overview

Hunan Warrant Pharmaceutical Co.,Ltd manufactures and sells pharmaceutical products in China. It offers medicines in the areas of digestive, respiratory, anti-infection, diabetes, cardiovascular, cerebrovascular, and other fields. The company also provides APIs and Intermediates. Hunan Warrant Pharmaceutical Co.,Ltd was founded in 2001 and is based in Changsha, China.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.warrant.com.cn](https://www.warrant.com.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:11.000Z

**Overall: B (0.34)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 35 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 8.45% |  |
| Net Profit YoY | 53.94% |  |
| P/B Ratio | 3.61 |  |
| Dividend Ratio | 0.75% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 7514340467.21 |  |
| Revenue | 1495199344.22 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 11.40% | B |
| Profit Margin | 15.00% | A |
| Gross Margin | 57.28% | B |
| Revenue YoY | 8.45% | B |
| Net Profit YoY | 53.94% | B |
| Total Assets YoY | 31.14% | A |
| Net Assets YoY | 10.73% | B |
| Cash Flow Margin | 148.13% | B |
| OCF YoY | 8.45% | B |
| Turnover | 0.52 | C |
| Gearing Ratio | 35.93% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Hunan Warrant Pharmaceutical Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "8.45%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "53.94%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "3.61",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.75%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "7514340467.21",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1495199344.22",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "11.40%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "15.00%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "57.28%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "8.45%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "53.94%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "31.14%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "10.73%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "148.13%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "8.45%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.52",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "35.93%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 33.50 | 79/215 | 50.11 | 34.41 | 29.40 |
| PB | 3.61 | 155/215 | 4.00 | 3.56 | 3.11 |
| PS (TTM) | 5.03 | 125/215 | 5.32 | 4.73 | 4.30 |
| Dividend Yield | 0.75% | 113/215 | 2.02% | 0.97% | 0.86% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2025-04-02T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 55.63 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688799.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688799.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/688799.SH/news.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**